Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR). - Trial NCT06399341
Access comprehensive clinical trial information for NCT06399341 through Pure Global AI's free database. This phase not specified trial is sponsored by Elpen Pharmaceutical Co. Inc. and is currently Completed. The study focuses on Papillomavirus Infections. Target enrollment is 524 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Elpen Pharmaceutical Co. Inc.
Timeline & Enrollment
N/A
Sep 01, 2021
Apr 30, 2023
Primary Outcome
The assessment of effectiveness of PAPILOCARE® in the regression of cervix cytological abnormalities caused by HPV.
Summary
The present study is a multicenter, open, non-interventional, prospective observational
 clinical study for the evaluation of the effectiveness of Papilocare® (medical device with CE
 mark) in the regression of cervix cytological abnormalities caused by HPV.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06399341
Device Trial